In a double-blind trial alprenolol IOO mg four times daily or placebo was given to 87 patientsfor one year from onset of their acute myocardial infarction. Patients were assessed on five occasions after their discharge from hospital. The mortality and hospital readmission rates were not significantly different in the two groups. This also applied to the incidence of cardiac failure, exertional dyspnoea, andfrequency of ventricular ectopic beats. The incidence of angina pectoris and the consumption of trinitrin were also not significantly different. The patients taking alprenolol had a significantly better rehabilitation rate judged by return to work. No injurious effect of alprenolol on the myocardium was observed using heart volume measurements as a criterion. There was a significant fall in resting systolic blood pressure between three months and one year in the patients on alprenolol and the systolic blood pressure during exercise on alprenolol was also significantly lower. Most patients felt better when exercised while taking alprenolol but there was no significant difference in the frequency of angina or ischaemic changes in the electrocardiogram during exercise with or without alprenolol. Ventilation and 02 uptake at rest and during exercise were lower on alprenolol. No bronchoconstrictor effect from alprenolol was detected.
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Drugs capable of blocking the activity of the beta adrenergic receptors and having antiarrhythmic properties have been in use in the management of ischaemic heart disease for about six years, but the therapeutic indications and benefits to be derived have yet to be finalized. Further investigation is also needed to determine whether deleterious effects occur from long-term therapy. Snow (I965) reported a significant reduction in mortality in acute myocardial infarctiontreated with propranolol. Norris, Caughey, and Scott (I968) reported a double blind trial on 454 patients with acute myocardial infarction treated with propranolol or placebo and found no difference in mortality or clinical course between treated and control groups. These trials dealt only with the period of inpatient management. Of patients who suffer a myocardial infarction, 20-60 per cent subsequently develop angina pectoris (Yater et al., 1948; Gertler et al., I95I) . Several workers (Gillam and Prichard, I965; Wolfson et al., I966; Hickie et al., 1970) after myocardial infarction is more common in patients who had a serious ventricular arrhythmia during their stay in hospital (Denborough et al., I968) and that sudden death is more common in subjects who have ventricular premature beats (Weiss et al., I969) . To assess the effects of beta adrenergic receptor blockade on these aspects a doubleblind trial was undertaken using the drug alprenolol (Aptin). A one-year follow-up was carried out to determine whether the pharmacological properties of alprenolol (Ablad, Bro- gard, and Ek, I967) would affect the symptomatic course or objective findings in patients with ischaemic heart disease.
The trial was arranged in two parts, the first assessing the effects on mortality, recurrent chest pain, and incidence of serious ventricular arrhythmias during the patient's stay in the coronary care unit (Briant and Norris, I970) . No significant difference in mortality or incidence of serious ventricular arrhythmia was found in this period between the patients on treatment and those on placebo.
has chest pain suspicious of myocardial infarction. Directly after admission, treatment was started taking tablets from the bottle next in order numerically. These had been prepared in random order by the hospital pharmacist who retained the key. Any patient who later did not have the diagnosis of myocardial infarction proven by the usually accepted criteria was withdrawn from the trial. Patients were also excluded if contraindications to a-blockade were present. These are heart block, systolic blood pressure of less than go for one hour, pulmonary oedema, sinus bradycardia of less than 50 beats per minute, and bronchial asthma.
Clinical follow-up Of the II9 patients in the first part of the trial, 9 died, I0 were withdrawn because of complications, and I3 were excluded because diagnostic criteria were not fully met; 87 continued into the second part of the trial, and to receive alprenolol 100 mg or placebo six-hourly while-in hospital and after discharge when supplies of tablets were dispensed at six-weekly intervals by the hospital pharmacy. This was considered a satisfactory surveillance of the patients' compliance with the trial, as failure to take the tablets regularly would result in a delayed visit to the pharmacy. This did not happen with any of the patients who completed the trial. After discharge from hospital the patients were seen by the same observer at 6 weeks, and at 3, 6, 9, and I2 months. At these times they were examined and the following additional data were obtained: electrocardiogram, heart volume, serum cholesterol, fatty acid esters, and haematocrit. Heart volume was determined from posteroanterior and left lateral chest films using formula L x B x D x o045, as described by Cooley and Schreiber (I967). Of the 87 patients discharged from hospital, 3 would not participate and 6 failed to keep appointments leaving 78 trial patients.
Exercise study A group of 30 patients (IS on treatment and IS on placebo) was given two exercise tests. The first of these tests (with two exceptions in each group) was made on 'normal' treatment and the second was made after stopping 'normal' treatment for at least I8 hours and taking the alternative tablets two hours before the study. The two exceptions in each group had their studies in the reverse order.
The study consisted of a 3-minute rest period followed by treadmill walking at 2*5 m.p.h. for a total of I2 minutes and then a 5-minute recovery period. The exercise was performed at three gradients: 3 minutes at 4 per cent, 3 minutes at 8 per cent, and 6 minutes at I6 per cent. All but 4 patients (2 from each group) completed the full exercise programme: 2 of these could not complete the highest level on treatment or control tablets, i completed it only on treatment, and the fourth only on control tablets.
The electrocardiogram was monitored throughout the study and the instantaneous rate and minute-by-minute count recorded by a cardiotachometer and heart beat counter (Philips). The expired air was passed through an 8-litre mixing chamber to a gas meter (Parkinson and Cowan C.D.4) arranged to give a signal at each litre. The expired air was analysed by side-arm sampling after the mixing chamber. The oxygen concentration was measured with a paramagnetic oxygenanalyser (Servomex controls) and the carbon dioxide concentration with a katapherometer (Godart), both instruments being connected to a digital voltmeter (Hewlett-Packard) from which readings were taken each minute. Respiratory frequency was measured by a pneumotachograph (Mercury Electronics). The respiratory frequency, minute volume in litres, and the instantaneous heart rate were recorded on an ultraviolet recorder (S.E. Laboratories). Electrocardiogram tracings and blood pressure measurements were taken at regular intervals throughout the study.
Calculations The oxygen uptake and RQ were calculated for each minute of the study. The averages were taken of the 3-minute rest period, the last 2 minutes at 4 and 8 per cent and the last 3 minutes at i6 per cent. It is probable that a steady state had not been reached at the lower levels but certainly would have been at the highest level. Because of a weight discrepancy between the groups (control group mean 74.7 kg, treatment group 70o6 kg) and a big variation of weight within the groups (Table 4 ) a correction was made for ventilation and oxygen uptake to a standard weight of 65 kg. To make this correction at rest was considered misleading because the patients varied widely in obesity. In grade walking however the external work is closely related to the total body weight, and it was thought reasonable to make this correction for the exercise measurements, leaving the resting values uncorrected.
Statistical analysis The results from the year's trial were treated in two ways. Variables such as heart rate and serum cholesterol were compared within each of the control and treatment groups by a paired t test to detect any changes over the course of the year. The two groups were also compared with each other in unpaired t tests. The incidence of angina, readmissions, etc. was compared by means of a x2 contingency test.
The results of the exercise studies were compared by means of t tests. The whole group of 30 patients was compared on and off treatment using paired t tests. The subgroups of I5 patients were compared using paired t tests within the group or unpaired t tests when comparing the control and treatment subgroups. F tests were done on all the variables compared with t test, and no inferences were drawn if the F test showed a P <0o0o.
Results
Clinical follow-up Seven patients were withdrawn from the trial and i8 had readmissions (Table i) . These patients showed a similar incidence of heart failure and no significant difference in the readmission rate, between those on alprenolol and those on placebo. These results were not influenced by the patient's history before inclusion in the trial as the incidence of previous myocardial infarction and angina pectoris in the treatment and placebo groups is not significantly different (Table 2) . Six patients died (Table I) , 3 on alprenolol and 3 on placebo. An acute coronary event was responsible in all.
Angina pectoris (Table 2) At 3 months this was present in 59 per cent of patients on alprenolol and 47 per cent of those on placebo (difference not statistically significant). At i year the incidence was 53 per cent on treatment and 32 per cent on placebo. These differences were not statistically significant, and it is noteworthy that the two patients withdrawn from the trial because of severe angina of effort were found to have been on placebo. The symptoms of both improved appreciably when they were later given alprenolol.
Trinitrin consumption (Table 2 ) At 3 months 20-5 per cent on treatment and i8 per cent on placebo took trinitrin (no significant difference). At i year the incidence was I4-7 per cent in both groups.
Blood pressure The mean systolic blood pressure at 3 months and i year was not significantly different in the patients on alprenolol from those on placebo (Table 3) . However, there was a significant drop in systolic blood pressure between 3 months and i year in the patients taking alprenolol (P < o-oos). Resting heart rate ( Table 3) This was significantly lower in the patients taking alprenolol (P <o.ooi at 3 months, P <o.ooi at i year), compared with those on placebo.
Heart volume (Table 3) The mean volumes at 3 months and i year for patients on alprenolol and placebo were within the normal range described by Domenet, Evans, and Howarth (I963). There was no significant difference between the two groups and no significant change between 3 months and i year in patients on alprenolol or placebo.
Body weight (Table 3) There was no significant difference between the alprenolol and placebo groups at 3 months or i year, but there was a significant fall in weight in patients on alprenolol between 3 months and i year (P <o.os).
Serum cholesterol (Table 3) There was no significant difference between placebo and alprenolol groups at 3 months or i year, but there was a significant fall in serum cholesterol in patients taking alprenolol between 3 months and i year (P <o-ooi).
, Serum fatty acid esters (Table 3) Patients taking alprenolol had significantly higher levels at 3 months (P < o-oi), but the difference was no longer significant at i year because of a rise in the patients on placebo and a fall in those taking alprenolol.
(b) Exercise studies Heart rate A highly significant difference in heart rate between the control and treatment groups was found both on their normal treatment and alternative treatment at all levels of exercise. The difference was significant at rest, became highly significant at all levels of exercise, and was highly significant when comparing the heart rate over the 5-minute recovery period (Tables 5 and 6). The difference was more obvious between two studies in the control group than between those in the treatment group, and this is probably a reflection of a carry-over effect in the alprenolol group stopping treatment and being tested while taking the placebo i8 to 24 hours later ( Fig.) .
Blood pressure There was a highly significant drop in resting systolic blood pressure when the control group took alprenolol for the day of the exercise, but the rise in blood pressure when the treatment group stopped treatment for i8 to 24 hours was not significant, again probably due to a carry-over effect. However, there was a highly significant difference in systolic pressure at maximum exercise both within the groups and between the groups (Tables 5 and 6 ). The blood pressure after 5 minutes of recovery showed similar differences to those found at rest. Weight (kg) 70-6 I15 74-7 2-6 Height (cm) I72-I i-6 I73.9
Occurrence of ectopic beats More of the control group had ectopic beats, both at rest and on exercise, and on placebo or alprenolol, than the alprenolol group (Tables 5 and 6 ). This difference, and the difference in frequency of ectopic beats, was not statistically significant, due to the fairly low incidence and large variation in the number of ectopic beats in those patients affected.
Angina pectoris There was a lower incidence, statistically insignificant, of angina pectoris during exercise in all subjects when they received alprenolol. The incidence was also lower overall in the group who had been taking alprenolol over 8 to I2 months.
Ischaemic changes in electrocardiogram There was no difference in incidence of ST changes in the electrocardiogram. Those patients who developed electrocardiographic changes did so on both alprenolol and placebo, and the occurrence of these changes did not correlate with the incidence of angina pectoris.
Spirometry Spirometry (vital capacity and FEV1) was measured on each patient before the studies to determine any measurable bronchoconstriction, but there was no difference between the groups (Tables 5 and 6 ).
Ventilation There was no significant difference between the groups at rest, though ventilation was a little lower when the subject was taking alprenolol. This trend was more obvious on exercise (Tables 5 and 6 ). This was shown in the results which had been corrected for weight, but the same differences were more conspicuous in the uncorrected data. Again the difference in the control group on and off alprenolol was more obvious than in the treatment group and was significantly different (P <0o025).
Respiratory frequency There was no difference either at rest or on exercise (Tables 5  and 6 ).
Oxygen uptake The oxygen uptake at rest was significantly lower (by I2-9%) in the treatment group receiving alprenolol than in the control group receiving placebo (P <°°5).
The difference in mean weight (5 5%) is unlikely to account for the whole difference at rest. On exercise there was a difference in the same direction, but this was significant (P < o o5) only within the placebo group compared on and off alprenolol (Tables 5 and 6 ).
TA BL E Respiratory quotient There was no obvious difference in RQ either at rest or on exercise (Tables 5 and 6 ). Discussion Alprenolol, like propranolol, has a direct depressant action on myocardial contractility, but, unlike propranolol, this effect usually occurs at dose levels considerably in excess of that necessary for ,B-blockade (Ablad et al., I967) . In the patients taking alprenolol either the depressant effect or the removal of sympathetic stimulation of the myocardium might be expected to result in exertional dyspnoea or overt cardiac failure more frequently than in similar patients receiving placebo. In this trial, the incidence of these events was not significantly different in the two groups (Tables i and 2 also no evidence of an injurious effect on the myocardium as gauged from the heart volume measurements (Table 3) which show no significant difference between the alprenolol and placebo groups and no significant change in the alprenolol groups between 3 months and I year.
The incidence of angina pectoris at the end of i year was apparently greater in the patients taking alprenolol (Table 2) but not significantly so. However, this finding is not supported by the figures on trinitrin consumption (Table 2) and is also the converse of the findings during the exercise studies. It could be inferred from this that interrogation of patients at routine visits is not a reliable guide to the true incidence of angina of effort especially when compared with interrogation directly after the completion of a set level of exercise.
Most investigators (Wolfson and Gorlin, I969; Craven and Pitt, i968; McKenna et al., i966) who have studied the effects of ,Bblockade on coronary blood flow have interpreted their results to mean that ,-blockers may cause coronary vasoconstriction. It is possible however that this effect is outweighed by the advantages of the reduction in cardiac work, and therefore myocardial oxygen consumption produced by the ,8-blockade or other mechanisms (Parratt and Wadsworth, I969) .
The numbers of patients taking trinitrin in the two groups were similar (Table 2) but fewer trinitrin tablets were consumed by the patients on alprenolol ( Table 2 ). The difference is not statistically significant but is influenced by the large variance in trinitrin consumption.
A fall in the resting systolic blood pressure in the period 3 months to i year occurred in the patients taking alprenolol (Table 3) . A comparable fall in blood pressure has been observed by Arstila, Iisalo, and Kallio (I969) in a clinical trial of alprenolol in angina pectoris. This gradual fall in blood pressure over a long period has been observed by others Prichard and Gillam (I966) . It has been stated that the rate of atherogenesis is directly related to the blood pressure, and that lowering the blood pressure favourably affects the incidence of some of the complications of atherosclerosis in man (Deming, I968) . The observed fall in blood pressure may therefore favourably affect the course of ischaemic heart disease. The systolic blood pressure during the exercise studies was also lower when the subject was on alprenolol (Tables 5 and 6 ). This, coupled with the lower heart rate (Tables 5 and 6 (Tables 5 and 6 ). The fall in weight of patients taking alprenolol over a long period could possibly be due to an appetite suppressant effect. Most of the patients noted an improvement in appetite after stopping the drug at the end of a year. 
